MPT

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-02issueIssued info_card
4. 2026-10-02issueIssued notice
5. 2026-10-02srcAdverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis
6. 2026-10-02srcSerotonin toxicity of serotonergic psychedelics
7. 2026-10-02srcFlashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants
8. 2026-10-02srcDimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.
9. 2026-10-02srcHallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases
10. 2026-10-02srcThe abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
11. 2026-10-02srcSerotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.
12. 2026-10-02srcStructure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties
13. 2026-10-02srcThe fumarate salts of the N-isopropyl-N-methyl derivatives of DMT and psilocin
14. 2026-10-02srcDMT analogues: N-ethyl-N-propyl-tryptamine and N-allyl-N-methyltryptamine as their hydro-fumarate salts
15. 2026-10-02srcN-Methyl-N-propyltryptamine (MPT)
16. 2026-10-02srcNonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice
17. 2026-10-02srcPharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status
18. 2026-10-02srcTolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.
19. 2026-10-02srcPharmacologic Activity of Substituted Tryptamines at 5-HT2A, 5-HT2C, 5-HT1A Receptors and SERT
20. 2026-10-02srcThe hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator
21. 2026-10-02srcIndolealkylamines: biotransformations and potential drug-drug interactions
22. 2026-10-02srcPsychedelics and the human receptorome
23. 2026-10-02srcRecreational use, analysis and toxicity of tryptamines.
24. 2026-10-02srcToxicology and Analysis of Psychoactive Tryptamines.
25. 2026-10-02srcHallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents.
26. 2026-10-02srcPsychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions
27. 2026-10-02srcDifferential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
28. 2026-10-02srcTiHKAL entry #47: MIPT (N-isopropyl-N-methyltryptamine)
29. 2026-10-02srcMPT - PsychonautWiki
30. 2026-10-02srcMethylpropyltryptamine - HandWiki
31. 2026-10-02publicationPublication — publishagent-psx
32. 2026-10-02revisionr1.a1
33. 2026-10-02rulingRuling — psx:substance/mpt/proposal/article_section_proposals/8bededa1-b91b-41c7-89ca-04302da84b94founder
34. 2026-10-02rulingRuling — psx:substance/mpt/proposal/article_section_proposals/fb8b9b1a-66a9-42ac-817b-f6509d29f91cfounder
35. 2026-09-04issueIssued emergency
36. 2026-09-04issueIssued info_card
37. 2026-09-04issueIssued notice
38. 2026-06-04proposal20 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
39. 2026-06-04publicationPublication — backfill
40. 2026-05-11revisionRevision 1
41. 2026-05-11absenceSearched ClinicalTrials.gov for "methylpropyltryptamine MPT" — no results
42. 2026-05-11absenceSearched PubMed for "MPT methylpropyltryptamine pharmacology" — no results
43. 2026-05-11absenceSearched PubChem for "N-methyl-N-propyltryptamine / [2-(1H-indol-3-yl)ethyl](methyl)propylamine" — no results
44. 2026-05-11genGeneration — pipeline-v5 · with 5 morepipeline-v5
45. 2026-05-11rungeneration run

The same entries, as forms: six forms.